Metabolic syndrome increases the risk of aggressive prostate cancer detection

Juan Morote, Jordi Ropero, Jacques Planas, Juan M. Bastarós, Gueisy Delgado, José Placer, Anna Celma, Inés M. De Torres, Joan Carles, Jaume Reventós, Andreas Doll

Research output: Contribution to journalArticleResearchpeer-review

47 Citations (Scopus)


Objective To further examine the association between metabolic syndrome (MS), prostate cancer (PC) detection risk and tumour aggressiveness. Patients and Methods From 2006 to 2010, 2408 men not receiving 5α-reductase inhibitors were scheduled for prostatic biopsy due to PSA above 4 ng/mL and/or abnormal digital rectal examination. MS was evaluated according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition. Tumour aggressiveness was evaluated through biopsy Gleason score, clinical stage and risk of biochemical recurrence after primary treatment. Results The rates of PC detection were 34.5% and 36.4% respectively in men with and without MS, P = 0.185. High grade PC rates (Gleason score 8-10) were 35.9% and 23.9% respectively, P < 0.001. The advanced disease rates (cT3-4 N0-1 M0-1) were 17% and 12.7% respectively, P = 0.841. The high risk PC rates (cT2c-4 or Gleason score 8-10 or PSA > 20) were 38.5% and 33.0% respectively, P = 0.581. Multivariate analysis confirmed that MS was not associated with the risk of PC detection but it was associated with an increased risk of high grade tumours (odds ratio 1.75, 95% CI 1.26-2.41), P < 0.001. Conclusion MS seems not be associated with an increased risk of PC detection but it is associated with an increased risk of more aggressive tumours. © 2012 BJU International.
Original languageEnglish
Pages (from-to)1031-1036
JournalBJU International
Issue number7
Publication statusPublished - 1 Jun 2013


  • aggressive
  • metabolic syndrome
  • prostate cancer
  • risk


Dive into the research topics of 'Metabolic syndrome increases the risk of aggressive prostate cancer detection'. Together they form a unique fingerprint.

Cite this